Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 28 results
Filters: First Letter Of Title is T  [Clear All Filters]
Found 28 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

T

Saharia KK, Petrovas C, Ferrando-Martinez S, et al. "Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells." PLoS ONE. 2016;11(7):e0158262.
Luetkemeyer AF, Kendall MA, Nyirenda M, et al. "Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs." J. Acquir. Immune Defic. Syndr.. 2014;65(4):423-8.
de Perio MA, Gomez FJ, Frame PT, Fichtenbaum CJ. "A truvada hypersensitivity reaction simulating abacavir hypersensitivity." AIDS. 2007;21(16):2252-3.
Deeks SG, Gange SJ, Kitahata MM, et al. "Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America." Clin. Infect. Dis.. 2009;49(10):1582-90.
Smith K, Zheng L, Bosch R, et al. "Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174." AIDS Res. Hum. Retroviruses. 2010;26(4):425-32.
Fichtenbaum CJ, Yeh T-min, Evans SR, Aberg JA. "Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087." J Clin Lipidol. 2010;4(4):279-87.
E Cardozo F, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM. "Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration." PLoS Pathog.. 2017;13(7):e1006478.
Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. "Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies." Clin. Infect. Dis.. 2009;49(3):473-6.
Funderburg NT, Xu D, Playford MP, et al. "Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity." Antivir. Ther. (Lond.). 2017;22(1):71-75.
M Villarino E, Scott NA, Weis SE, et al. "Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid." JAMA Pediatr. 2015;169(3):247-55.
Kassaye SG, Grossman Z, Balamane M, et al. "Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC." Clin. Infect. Dis.. 2016.
Almeida C-AM, Bronke C, Roberts SG, et al. "Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes." J. Immunol.. 2011;187(5):2502-13.
Ouyang Z, Buzon MJ, Zheng L, et al. "Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir." Open Forum Infect Dis. 2015;2(2):ofv045.
Mukherjee PK, Chen H, Patton LL, et al. "Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants." AIDS. 2017;31(1):81-88.
Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. "Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis." PLoS ONE. 2008;3(4):e1915.
Yonkers NL, Rodriguez B, Milkovich KA, et al. "TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection." J. Immunol.. 2007;178(7):4436-44.
Havlir DV, Kendall MA, Ive P, et al. "Timing of antiretroviral therapy for HIV-1 infection and tuberculosis." N. Engl. J. Med.. 2011;365(16):1482-91.
Wilkin TJ, Su Z, Krambrink A, et al. "Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients." J. Acquir. Immune Defic. Syndr.. 2010;54(5):470-6.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Sterling TR, Scott NA, Miro JM, et al. "Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons." AIDS. 2016;30(10):1607-15.
Sterling TR, M Villarino E, Borisov AS, et al. "Three months of rifapentine and isoniazid for latent tuberculosis infection." N. Engl. J. Med.. 2011;365(23):2155-66.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
Mulligan K, Zackin R, Von Roenn JH, et al. "Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial." J. Clin. Endocrinol. Metab.. 2007;92(2):563-70.
Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. "Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms." AIDS. 2013;27(6):967-72.
Johnson DC, Chasela C, Maliwichi M, et al. "Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi." PLoS ONE. 2012;7(7):e41011.
Reynolds NR, Testa MA, Su M, et al. "Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial." J. Acquir. Immune Defic. Syndr.. 2008;47(1):62-8.
Thomas AS, Jones KL, Gandhi RT, et al. "T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy." PLoS Pathog.. 2017;13(9):e1006629.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.